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Abstract
Background: The chemopreventive effects of dietary phytochemicals on malignant tumors have
been studied extensively because of a relative lack of toxicity. To achieve desirable effects,
however, treatment with a single agent mostly requires high doses. Therefore, studies on effective
combinations of phytochemicals at relatively low concentrations might contribute to
chemopreventive strategies.
Results: Here we found for the first time that co-treatment with I3C and genistein, derived from
cruciferous vegetables and soy, respectively, synergistically suppressed the viability of human colon
cancer HT-29 cells at concentrations at which each agent alone was ineffective. The suppression of
cell viability was due to the induction of a caspase-dependent apoptosis. Moreover, the
combination effectively inhibited phosphorylation of Akt followed by dephosphorylation of
caspase-9 or down-regulation of XIAP and survivin, which contribute to the induction of apoptosis.
In addition, the co-treatment also enhanced the induction of autophagy mediated by the
dephosphorylation of mTOR, one of the downstream targets of Akt, whereas the maturation of
autophagosomes was inhibited. These results give rise to the possibility that co-treatment with I3C
and genistein induces apoptosis through the simultaneous inhibition of Akt activity and progression
of the autophagic process. This possibility was examined using inhibitors of Akt combined with
inhibitors of autophagy. The combination effectively induced apoptosis, whereas the Akt inhibitor
alone did not.
Conclusion: Although in vivo study is further required to evaluate physiological efficacies and
toxicity of the combination treatment, our findings might provide a new insight into the
development of novel combination therapies/chemoprevention against malignant tumors using
dietary phytochemicals.
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Background
Malignant tumors are a leading cause of death in many
countries and chemoprevention has become an impor-
tant issue. Since chemoprevention with nontoxic agents
could be one approach to reducing the incidence of can-
cers, anticancer effects of dietary phytochemicals includ-
ing polyphenols have recently been studied [1,2]. It has
been suggested that a combination of agents is more effec-
tive than any single constituent in achieving chemopre-
ventive effects [3]. For this reason, studies on synergistic
effects of different phytochemicals might contribute to the
chemopreventive strategies against malignant tumors.
Genistein is a soy-derived isoflavone with multiple bio-
chemical effects, including the alteration of cell cycle-reg-
ulatory kinase activities [4,5]. Previous studies indicated
that genistein induced apoptosis, enhanced the induction
of apoptosis by chemotherapeutic agents, and increased
radiosensitivity in several cancer cell lines [4,6]. Genistein
is also known as an estrogen receptor (ER) agonist, and
that genistein can antagonise the proliferation of breast
cancer cells by estradiol [7]. However, most transcription
activation bioassays are not able to show an estrogen
receptor antagonism of genistein, and genistein acts addi-
tive to estradiol in theses systems [8]. It is therefore con-
troversial whether anti-proliferative effect of genistein is
ER-dependent or not [9].
Indole-3-carbinol (I3C), derived from Cruciferous vegeta-
bles, has been shown to suppress the growth of various
tumor cells including colon cancer cells by arresting the
cell cycle at G1/S and inducing apoptosis in vitro [10], tar-
geting molecules such as Bcl-2, mitogen-activated protein
kinase (MAPK), cyclin D1, and the cyclin-dependent
kinase (CDK) inhibitors p21, p27 [10] and p15 [11]. I3C
is also known as an androgen receptor (AR) antagonist.
Previous reports suggest that I3C is able to inhibit AR
mediated proliferation of prostate cancer cells [12].
Both genistein and I3C have been reported to down-regu-
late the phosphatidylinositol 3-kinase (PI3K)/Akt signal-
ing pathway. Akt is a serine/threonine protein kinase, also
known as protein kinase B (PKB), which plays a critical
role in suppressing apoptosis [13,14] by regulating its
downstream pathways [15-18]. On the other hand, Akt
also phosphorylates mammalian target of rapamycin
(mTOR), which has been reported to inhibit the induc-
tion of macroautophagy (hereafter referred to as
autophagy) [19,20].
Autophagy is the regulated process by which cytoplasmic
constituents are recruited to lysosomes for degradation
[19,21,22]. The autophagic pathway begins with the for-
mation of a double-membrane vesicle called the
"autophagosome" which engulfs organelles or long-lived
proteins and matures into an acidic single-membrane
autophagosome that fuses with a lysosome to become the
"autolysosome", whose content is degraded [20,21].
Recently, the relationship between autophagy and apop-
tosis has been studied extensively [23-26]. Although the
molecular mechanism underlying this interconnection is
still obscure, several reports have suggested autophagy to
be induced by anticancer treatments with γ-irradiation or
chemotherapeutic agents, to protect cancer cells from
apoptosis [20,26-28]. Thus, inhibition of autophagy may
induce apoptosis [29-36].
We here found for the first time that co-treatment with
I3C and genistein synergistically induced apoptosis in
human colon cancer HT-29 cells by simultaneously inhib-
iting the phosphorylation of Akt and progression of the
autophagic process.
Results
Co-treatment with I3C and genistein synergistically 
inhibits the viability of HT-29 cells
To examine the effect of I3C or genistein on the human
colon cancer cell line HT-29, a cell viability assay was first
performed. HT-29 cells were treated with I3C at concen-
trations ranging from 75 μmol/L to 1200 μmol/L or with
genistein at 20 μmol/L to 320 μmol/L, for 48 h. As shown
in Fig. 1A, neither I3C at up to 300 μmol/L nor genistein
at up to 160 μmol/L had any significant inhibitory effect
on cell viability. The time dependent-suppressive effect of
I3C and/or genistein on viability was assessed further and
remarkable suppression was observed when 300 μmol/L
of I3C and 40 μmol/L of genistein were combined, reduc-
ing the cell viability to 87.0% after 24 h and 52.6% after
48 h, whereas each agent alone had no inhibitory effect on
cell viability over the 48 h (Fig. 1B). To further determine
whether the inhibitory effects were synergistic, we ana-
lyzed CI value of the combination using CalcuSyn soft-
ware. As shown in Fig. 1C, the CI values remained < 1 over
the entire range of Fa values, indicating that I3C and gen-
istein are synergistic in terms of inhibitory effect on cell
viability.
Co-treatment with I3C and genistein synergistically 
induces apoptosis
We next investigated whether the cell death induced by
the co-treatment with I3C and genistein could be apopto-
sis. We analyzed the cell cycle distribution by flow cytom-
etry and observed a significant increase in the sub-G1
population among the cells co-treated with I3C and gen-
istein for 48 h. In contrast, neither I3C nor genistein alone
had any effect on the sub-G1 population (Fig. 2A). More-
over, the increase in the sub-G1 population caused by the
co-treatment was abrogated by the pan-caspase inhibitor
z-VAD-fmk (Fig. 2B), suggesting it to be due to caspase-
dependent apoptosis. To further characterize this cellMolecular Cancer 2009, 8:100 http://www.molecular-cancer.com/content/8/1/100
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Inhibitory effects of I3C and genistein on cell viability in human colon cancer HT-29 cells Figure 1
Inhibitory effects of I3C and genistein on cell viability in human colon cancer HT-29 cells. A, Viability of HT-29 
cells 48 h after exposure to increasing doses of I3C or genistein as indicated. B, Time-dependent viability of HT-29 cells not 
treated (black circle) or treated with DMSO (black triangle), I3C (300 μmol/L) (black square), genistein (40 μmol/L) (black tri-
angle), or a combination of I3C (300 μmol/L) and genistein (40 μmol/L) (white circle) for up to 2 days. The cell viability assay 
was performed as described in Materials and Methods. Columns and points, mean (n = 3); bars, SD. *, P < 0.05, significantly dif-
ferent compared with the DMSO-treated control. GEN, genistein. C, HT-29 cells were exposed to increasing concentrations 
of I3C and genistein, either alone or in a fixed ratio of 7.5:1, for 48 h, as described in Materials and Methods. The Fa-CI plot 
was constructed using experimental data points (dark circles) and by simulating CI values over the entire range of Fa values 
(line) using CalcuSyn software. Synergy, additivity, and antagonism are defined as CI<1, CI = 1, and CI>1, respectively.
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Effects of co-treatment with I3C and genistein on apoptosis in HT-29 cells Figure 2
Effects of co-treatment with I3C and genistein on apoptosis in HT-29 cells. A, The sub-G1 population was assessed 
by flow cytometry as described in Materials and Methods after exposure to the indicated agents for 24 or 48 h. Columns, mean 
(n = 3); bars, SD. *, P < 0.05, significantly different compared with the DMSO-treated control. B, HT-29 cells were exposed to 
DMSO or a combination of I3C (300 μmol/L) and genistein (40 μmol/L) for 48 h or pretreated with z-VAD-fmk (20 or 100 
μmol/L) for 2 h followed by exposure to the combination for 48 h. The sub-G1 population was quantified by flow cytometry as 
described in Materials and Methods. Columns, mean (n = 3); bars, SD. *, P < 0.05, significantly different compared with the com-
bined treatment. C, Cells were exposed to DMSO (control), a combination of I3C (300 μmol/L) and genistein (40 μmol/L), or 
doxorubicin (1 μmol/L) for 48 h, stained with DAPI, and observed under a fluorescence microscope as described in Materials 
and Methods. Doxorubicin was used as a positive control to induce apoptosis. Bars, 20 μm. D, HT-29 cells were exposed to 
the indicated agents for 48 h. The expression of PARP, caspase-8, caspase-9 and cleaved caspase-3 proteins was analyzed by 
western blotting. β-actin was used as a loading control. -, treated with DMSO. GEN, genistein.
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death, we performed DAPI staining. As shown in Fig. 2C,
cells co-treated with I3C and genistein showed nuclear
fragmentation and chromatin condensation. Collectively,
these features are characteristic of apoptosis. To confirm
these results at the molecular level, we investigated the
cleavage of poly (ADP-ribose) polymerase (PARP) or acti-
vation of caspase-3, caspase-8, and caspase-9 by western
blotting. As shown in Fig. 2D, neither I3C nor genistein
alone could activate these caspases, although in combina-
tion they clearly cleaved PARP and these caspases to their
active forms. Collectively, these results provide evidence
that the cell death induced by the co-treatment with I3C
and genistein is caused by caspase-dependent apoptosis.
Co-treatment with I3C and genistein reduces 
phosphorylated Akt and its downstream targets
Previous reports indicated that either I3C or genistein
inhibited Akt activity through a reduction in its phospho-
rylation [4,10]. Once activated, Akt transduces signals to
downstream targets that control cell survival and inhibit
apoptosis [13,14]. To assess the involvement of the Akt
pathway in the apoptosis induced by the co-treatment
with I3C and genistein, the level of phosphorylated Akt
protein was investigated by western blotting. As shown in
Fig. 3A and 3B, phosphorylated Akt started to decrease 6
h after the co-treatment. Twelve hours after the co-treat-
ment caspase-3 started to be activated [see Additional file
1], suggesting that dephosphorylation of Akt occurs
before apoptosis.
In addition, we further investigated the expression of
phosphorylated caspase-9, a downstream target of Akt,
and found that the co-treatment significantly reduced the
level of phospho-caspase-9 (Ser196), resulting in activa-
tion of caspase-9. Since X chromosome-linked inhibitor
of apoptosis protein (XIAP) and survivin, inhibitor of
apoptosis protein (IAP) family members, have been
recently reported to be activated by Akt [17,18], we further
investigated the expression of the proteins. As shown in
Fig. 3A, both XIAP and survivin expression was markedly
downregulated by the combined treatment, consistent
with the inhibition of Akt phosphorylation by the treat-
ment.
Since mTOR is another downstream effector of Akt, we
further investigated phosphorylated mTOR expression by
western blotting. As shown in Fig. 3C, the co-treatment
clearly reduced the phosphorylated mTOR at 12 h.
Co-treatment with I3C and genistein induces 
autophagosome formation
Several reports indicate that PI3k/Akt signaling negatively
regulates autophagy through mTOR [19,37]. Recent stud-
ies have shown that the inhibition of Akt and its down-
stream target mTOR contributes to the initiation of
autophagy [38,39]. To investigate whether co-treatment
with I3C and genistein could promote autophagy via inhi-
bition of the Akt/mTOR pathway, we measured the
expression of microtubule-associated protein-1 light
chain-3 (LC3) protein by western blotting. During
autophagy, cytosolic LC3-I is conjugated with phosphati-
dylethanolamine and converted to LC3-II, and this proc-
ess is essential for the formation of autophagosomes.
Since LC3-II is present specifically on isolation membrane
and autophagosomes, its amount correlates with the
number of autophagosomes and serves as an indicator of
their formation [40]. We found an enhancement of LC3-
II expression in the cells co-treated with I3C and genistein
from 12 h up to 48 h (Fig. 4A). Moreover, the up-regula-
tion of LC3-II did not occur in the cells treated with either
agent alone (Fig. 4B).
We next investigated the localization of endogenous LC3
by immunofluorescent staining. It has been suggested that
LC3 is recruited to the autophagic membrane during the
induction of autophagy, and the formation of autophago-
somes is reflected by a punctate distribution of LC3 [41].
As shown in Fig. 4C, only a few LC3-positive puncta were
observed in HT-29 cells treated with DMSO control. On
the other hand, numerous LC3-positive puncta were
observed in the cells subjected to amino acid starvation,
by which autophagy has been induced [21]. In HT-29 cells
co-treated with I3C and genistein, numerous LC3-positive
puncta were observed, suggesting the accumulation of
autophagosomes. This result is consistent with LC3-II pro-
tein levels detected by western blotting (Fig. 4A and 4B).
Moreover, the numbers of puncta were reduced by 10
mmol/L of 3-MA (an autophagy inhibitor) [42], as
expected. These results suggest that the numbers of puncta
reflect autophagosomes, consistent with a previous report
[41].
We next further investigated cell structure by transmission
electron microscopy. As shown in Fig. 4D, many more
autophagic vesicles were observed in HT-29 cells co-
treated with I3C and genistein for 12 h than in untreated
cells. As a positive control of autophagy, HT-29 cells were
subjected to amino acid starvation for 12 h, showing
numerous autophagic vesicles.
Co-treatment with I3C and genistein does not induce 
autophagic cell death
It has been suggested that excessive autophagy ultimately
induces a type of cell death called autophagic cell death
(type II programmed cell death) [43]. To investigate
whether the cell death caused by the co-treatment with
I3C and genistein induces autophagic cell death, cell via-
bility was measured using the autophagy inhibitor 3-MA.
As shown in Fig. 5A, 3-MA could not restore cell viability
in the cells co-treated with I3C and genistein. We also ana-Molecular Cancer 2009, 8:100 http://www.molecular-cancer.com/content/8/1/100
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Expression of Akt and its downstream effectors following co-treatment Figure 3
Expression of Akt and its downstream effectors following co-treatment. A, After 48 h of exposure to the indicated 
agents, cell lysates were subjected to western blotting using antibodies against phospho-Akt (Ser473), total Akt, phospho-cas-
pase-9 (Ser136), caspase-9, XIAP or survivin. B and C, After exposure to the agents for the periods indicated, cell lysates were 
subjected to western blotting with anti-phospho-Akt (Ser473), anti-Akt (B), anti-phospho-mTOR (Ser2448), and anti-mTOR 
(C) antibodies. β-actin was used as a loading control. -, treated with DMSO. GEN, genistein.
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lyzed sub-G1 population besides the cell viability assay,
and found that autophagy inhibition by 3-MA alone or
the co-treatment with I3C and genistein clearly induced
apoptosis compared to the control, and the apoptosis
induced by the co-treatment was not inhibited by 3-MA
(Fig. 5B), consistent with the data from Fig. 5A. These
results suggest that the cell death caused by the combined
treatment with I3C and genistein is not a result of
autophagic cell death but apoptosis at least partially
through inhibiting autophagic process.
Co-treatment with I3C and genistein prevents progression 
of the autophagic process at a later step and disrupts the 
maturation of autophagosomes
It has been reported that an enhancement of LC3 expres-
sion detected by western blotting does not necessarily
reflect an increase in autophagy, but also indicates inhibi-
tion of the autophagic process at a later step, resulting in
the accumulation of pre-matured autophagosomes
[40,44]. Autophagosomes fuse with lysosomes later in the
autophagic process forming autolysosomes, the content
of which are eventually degraded. The process is known to
be accompanied by an increase in the acidity of the lumen
followed by the development of acidic vesicular
organelles (AVOs) [45]. To quantify the development of
AVOs, cells co-treated with I3C and genistein were stained
with acridine orange and analyzed by flow cytometry.
Acridine orange concentrates in acidic vesicles such as
matured autophagosomes including autolysosomes and
has been used as an indicator of autophagosomal matura-
tion [27,28,36]. As shown in Fig. 6, in the amino acid-
starved cells the strength of the bright red fluorescence (Y
axis) increased from 3.0% to 28.0%, indicating the devel-
opment of AVOs, and 3-MA suppressed the increase from
28.0% to 3.8%, indicating inhibition of the development
of AVOs in amino acid-starved cells. The cells co-treated
with I3C and genistein did not show significant develop-
ment of AVOs compared with the control. The results
could suggest that co-treatment with I3C and genistein
disrupted the maturation of autophagosomes into func-
tional autolysosomes by preventing the progression of the
autophagic process at a later stage.
Apoptosis is enhanced by inhibition of both Akt activity 
and progression of autophagy
Several studies have suggested that autophagy could pro-
tect cells by preventing them from undergoing apoptosis
and inhibition of autophagy enhances apoptosis [20,27-
36]. From previous reports and the present findings, we
hypothesized that the synergistic apoptosis induced by
the co-treatment with I3C and genistein might depend on
the simultaneous inhibition of Akt activity and the pro-
gression of autophagy. To investigate the effects of Akt's
inhibition, HT-29 cells were exposed to LY294002 (50
μmol/L), a PI3K-specific inhibitor, or Akt inhibitor IV
(1.25 μmol/L), a selective inhibitor of Akt with no effect
on PI3K or PDK1. Exposure of LY294002 or Akt inhibitor
IV for 48 h changed the localization of LC3 from diffuse
cytosolic staining in control cells to a punctate distribu-
tion as shown by the immunofluorescent staining of LC3
(Fig. 7A). These results would reflect the development of
Detection of autophagosomes following co-treatment Figure 4
Detection of autophagosomes following co-treat-
ment. A, After exposure to a combination of I3C (300 
μmol/L) and genistein (40 μmol/L) for the periods indicated, 
cell lysates were subjected to western blotting with an anti-
LC3 antibody. β-actin was used as a loading control. B, After 
exposure to the indicated agents for 48 h, cell lysates were 
subjected to western blotting with an anti-LC3 antibody. β-
actin was used as a loading control. -, treated with DMSO: C, 
HT-29 cells were exposed to DMSO (control) or a combina-
tion of I3C (300 μmol/L) and genistein (40 μmol/L) for 12 h 
with or without 10 mmol/L of 3-methyladenine (3-MA). As a 
positive control for the induction of autophagy, cells were 
subjected to amino acid starvation (AAS) by incubating them 
in amino acid-deprived medium for 12 h. After the incuba-
tion, cells were subjected to immunofluorescent staining for 
LC3 as described in Materials and Methods. Bars, 20 μm. D, 
HT-29 cells were exposed to DMSO (control) or a combina-
tion of I3C (300 μmol/L) and genistein (40 μmol/L) in com-
plete medium or subjected to AAS for 12 h. The cells were 
then harvested and subjected to transmission electron 
microscopy as described in Materials and Methods. White 
arrows, autophagic vesicle. N, nucleus. GEN, genistein.
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autophagosomes in the cells treated with LY294002 or
Akt inhibitor IV. Moreover, these agents increased the
strength of bright red fluorescence compared to the con-
trol in the flow cytometric analysis of acridine orange
staining, indicating the development of AVOs (Fig. 7B).
Collectively, LY294002 and Akt inhibitor IV were thought
to enhance the progression of autophagy consistent with
previous reports [46,47]. We next measured the sub-G1
population under conditions inhibiting both Akt activity
and autophagy. We treated HT-29 cells for 48 h with
LY294002 (50 μmol/L) or Akt inhibitor IV (1.25 μmol/L)
to inhibit the Akt activity and 3-MA (10 mmol/L) or
bafilomycin A1 (10 nmol/L), a specific inhibitor of vacu-
olar-type H+-ATPase, which has been reported to disrupt
the progression of autophagy at the later step by inhibit-
ing fusion between autophagosomes and lysosomes
[48,49], to inhibit autophagy. As shown in Fig. 7C, inhi-
bition of autophagy by 3-MA or bafilomycin A1 aug-
mented the sub-G1 population in more than an additive
fashion in HT-29 cells treated with LY294002 or Akt
inhibitor IV. These results give rise to a possibility that
inhibition of both Akt activity and autophagy augments
apoptosis, consistent with the hypothesis that co-treat-
ment with I3C and genistein synergistically induces apop-
tosis as a result of the simultaneous inhibition of Akt
phosphorylation and autophagy.
Discussion
Though high doses of single agents have been shown to
have potent antitumor effects, the chemopreventive prop-
erties of vegetables may result from interactions among
several components that potentiate the activities of any
single constituent. In the present study, we found a syner-
gistic antitumor effect by co-treatment with I3C and gen-
istein at concentrations more than four times lower than
those of each agent alone (Fig. 1A and 1B). We concluded
that the antitumor effect was due to apoptosis via inhibi-
tion of both Akt phosphorylation and the progression of
autophagy.
The PI3K/Akt pathway has been reported to play an
important role in the inhibition of apoptosis [13,14].
Once activated, Akt phosphorylates and inactivates sev-
eral proapoptotic proteins, including Bad [15] and cas-
pase-9 [16], thus inhibiting intrinsic apoptotic pathway.
Akt also inhibits the extrinsic death receptor-mediated
apoptotic pathway through up-regulation of FLICE inhib-
itory protein (FLIP) expression [50,51], which can inhibit
apoptosis as an antagonist of caspase-8 [52]. Akt thus
inhibits apoptosis by suppressing both the intrinsic and
extrinsic pathways. Moreover, recent studies have sug-
gested that XIAP or survivin is positively regulated by Akt
[17,18]. It has been also reported that I3C or genistein
alone inhibits the phosphorylation of Akt [4,10].
However, in the present study, neither agent alone
reduced the phosphorylation of Akt, whereas co-treat-
ment with I3C and genistein did (Fig. 3). We have also
found that caspase-9, known as a downstream target of
Akt, was dephosphorylated and cleaved to the active form
by the combined treatment, as expected. In addition, we
found the cleavage of caspase-8 by the combination treat-
ment. The combination also caused a reduction in XIAP
and survivin. Collectively, these results suggest that the
activation of caspase-9 and caspase-8 with suppression of
XIAP and survivin expressions via inhibition of the Akt
pathway contribute, at least in part, to the apoptotic cell
death caused by the co-treatment.
Genistein is known as one of the major phytoestrogens
that are structurally similar to estradiol, binding to estro-
gen receptor β (ERβ) with considerably higher affinity
than to estrogen receptor α (ERα)[53]. However, it is still
unknown whether the antiproliferative effects of genistein
in colon cancer cells involve the transcriptional regulation
mediated by estrogen receptors in addition to the tyrosine
kinase pathway [9]. I3C and its metabolite diindolylmeth-
ane (DIM) are known androgen receptor antagonist and
DIM is also an ER agonist like genistein [12]. Both I3C
and DIM caused anti-proliferative effects on prostate can-
cer cells via AR-mediated pathway [12]. In addition, both
ER and AR are expressed in normal intestine, including
the colon [54]. However, in HT-29 cells, the expression of
ERα, ERβ, and AR protein levels was undetectable [55].
We therefore consider that the anti-proliferative effect by
the combination of I3C with genistein is independent of
the nuclear receptor pathways.
mTOR is another downstream target of Akt, and inhibi-
tion of the PI3K/Akt/mTOR pathway has been shown to
initiate autophagy [19,37-39]. Increasing evidence has
suggested that several flavonoids induce autophagy
[56,57]. We next found that co-treatment with I3C and
genistein also caused dephosphorylation of mTOR, asso-
ciated with the formation of autophagosomes (Fig. 4C
and 4D). At the same time, we found that the progression
of the autophagic process was inhibited by the combina-
tion as mentioned below.
Several studies have suggested that inhibition of the mat-
uration of autophagosomes causes the accumulation of
pre-matured autophagosomes [29,30,40,44]. The matura-
tion of autophagosomes into autolysosomes is accompa-
nied by an increase in AVOs reflecting the acidity of the
lumen [45]. We found that the combination of I3C and
genistein did not develop AVOs, suggesting the matura-
tion of autophagosomes to be inhibited (Fig. 6). Addi-
tionally, we found the accumulation of LC3-II (Fig. 4A
and 4B) consistent with a report that inhibition of theMolecular Cancer 2009, 8:100 http://www.molecular-cancer.com/content/8/1/100
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autophagic process at the maturation step enhances LC3-
II expression [40]. Therefore, co-treatment with I3C and
genistein might promote the formation of autophago-
some, but prevent their maturation, though the precise
mechanism remains to be elucidated.
The role of the autophagic process in antitumor therapy
has not been clearly elucidated. To adapt to the stressful
conditions caused by anticancer therapies, cancer cells
undergo autophagy as a temporary survival mechanism.
The suppression of autophagy leads to apoptosis, thus
enhancing the antitumor effect [29-35]. On the other
hand, several anticancer treatments, including irradiation
and chemotherapeutic agents, have been reported to
induce autophagic cell death [20,27,38], which has no
characteristics of apoptosis, indicating autophagy to be a
crucial mechanism of the cancer cell death caused by these
treatments. In the present study, an autophagy inhibitor
3-MA could not reverse the loss of cell viability among
HT-29 cells caused by the combined treatment, suggesting
that the treatment does not induce autophagic cell death
(Fig. 5). The results raise the possibility that the suppres-
sion of autophagy by the co-treatment causes apoptosis.
In the present study, we found that inhibition of both Akt
phosphorylation and the progression of autophagy
enhanced apoptosis in HT-29 cells (Fig. 7C). Degtyarev et
al. have also demonstrated that blocking autophagy with
bafilomycin A1 enhanced apoptosis in tumor cells when
Akt activity was inhibited [58]. This report supports our
hypothesis that the mechanism underlying the synergistic
induction of apoptosis by the co-treatment with I3C and
genistein results from simultaneous inhibition of the
PI3K/Akt pathway and progression of the autophagic
process.
Sato et al. have suggested that autophagy is activated in
colorectal cancer in vitro and in vivo, and might contribute
to the survival of cancer cells [59]. Additionally, they
found a remarkable enhancement of apoptosis by inhibit-
ing autophagy. Bauvy et al. have reported that autophagy
delays sulindac sulfide-induced apoptosis in HT-29 cells,
suggesting autophagy to be a protective mechanism in this
cell line [34]. These reports suggest that stimulation of
autophagy may lead to enhanced tumor growth and that
therapies inhibiting autophagy may be effective against
colon cancer cells.
Finally, it is important to discuss physiological concentra-
tions and toxicity of I3C and genistein. According to the
previous reports, the plasma level of DIM converted from
I3C in people who received oral doses of 1 g I3C was
almost 1-5 μmol/L [60]. They have also shown that I3C
itself was not detected in plasma and the only DIM was
detected. Firestone et al. reported that I3C is converted
intracellularly into DIM in the cultured breast cancer cells
[61]. Furthermore, Bonnesen et al. indicated that the DIM
was about 9-15 times more toxic to human colon cancer
cells than I3C [62]. However, it is unknown how much
I3C is converted into DIM in the cultured HT-29 cells, and
we can hardly evaluate the physiological effects of I3C.
When 2, 4, or 8 mg/kg of genistein was orally adminis-
tered to human, the plasma concentrations of genistein
were 4.3-16.3 μmol/L [63]. Busby MG et al. reported that
the maximum plasma concentrations of total genistein
were 27.46 ± 15.38 μmol/L when 16 mg/kg of genistein
was orally administered [64]. In this regard, 40 μmol/L of
a plasma genistein may be achievable with oral intake of
purified genistein. They also reported toxic effects includ-
3-MA does not inhibit the cell death caused by co-treatment  with I3C and genistein Figure 5
3-MA does not inhibit the cell death caused by co-
treatment with I3C and genistein. Cell viability (A) and 
the sub-G1 population (B) in the HT-29 cells exposed to 
DMSO, 3-MA (10 mmol/L) or the co-treatment with I3C 
(300 μmol/L) and genistein (40 μmol/L) with or without 3-
MA (10 mmol/L) for 48 h. Cell viability and the sub-G1 popu-
lation were analyzed as described in Materials and Methods. 
Columns, mean (n = 3); bars, SD. *, P < 0.05, significantly dif-
ferent compared with the DMSO-treated control.
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ing hypophosphatemia, pedal edema and so on, though
they were not associated with clinical toxicity. Since their
observation is limited to a short period, further investiga-
tion of the toxicology over longer periods must be con-
ducted before clinical usage.
Although genistein and I3C are known to have antitumor
effects extensively, they also have been reported to stimu-
late carcinogenesis or growth of tumors. Genistein has
been found to inhibit the growth of human breast cancer
MCF-7 cells at high concentrations (above 20 μmol/L)
[65], but to stimulate the growth at a lower concentration
(200 nmol/L) [66]. Regarding in vivo studies, genistein has
been shown to have preventive effect in the azoxymeth-
ane-induced rat colon carcinogenesis model [67], whereas
genistein increased aberrant crypt foci by 1,2-dimethylhy-
drazine in rats fed diets containing genistein [68]. On the
other hand, I3C is known to exhibit chemopreventive
effects in experimental animal models, such as a sponta-
neous occurrence of endometrial carcinoma in female
Donryu rats [69], 7,12-dimethylbenz (a) anthracene
(DMBA) or N-methyl-N-nitrosourea (MNU) induced rat
carcinogenesis [70], or an aflatoxin B1-induced rat car-
cinogenesis [71]. However, several reports have suggested
that I3C enhances carcinogenesis in certain protocols,
such as a rat multiorgan carcinogenesis by sequential
treatment with diethylnitrosoamine (DEN), MNU and
dihydroxy-di-N-propyl-nitrosoamine (DHPN) [72], or a
rat 1,2-dimethylhydrazine (DMH) induced colon carcino-
genesis [73]. Collectively, effects of genistein and I3C on
malignant tumors are not fully established. Therefore, the
efficacy and risk potential of these dietry components
must be considered with careful attention, and further
investigation is required.
Conclusion
The present study is the first to show the efficacy of com-
bined treatment with naturally occurring flavonoids
which inhibit the PI3K/Akt pathway and autophagic proc-
ess. Although further studies are required to examine the
adverse health effects of the combination treatment with
I3C and genistein, including stimulating the induction
and growth of tumors, we believe that the present study
could be a clue to a novel strategy against malignant
tumors using dietary phytochemicals.
Co-treatment with I3C and genistein does not induce maturation of autophagosomes Figure 6
Co-treatment with I3C and genistein does not induce maturation of autophagosomes. Quantification of acidic 
vesicular organelles by acridine orange staining using flow cytometry. HT-29 cells treated with DMSO (control), amino acid-
deprived medium (AAS) in the presence or absence of 3-MA (10 mmol/L), or the combination of I3C (300 μmol/L) and genis-
tein (40 μmol/L) for 12 h were stained with acridine orange, and then subjected to a flow cytometric analysis as described in 
Materials and Methods. Left, FL1-H indicates the intensity of green fluorescence that is endogenous to the nucleus. FL3-H indi-
cates the intensity of red fluorescence. Top of the grid was considered as AVOs. GEN, genistein. Right, Columns, mean (n = 3); 
bars, SD. *, P < 0.05, significantly different compared with the control.
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Effects of simultaneous inhibition of Akt activity and progression of autophagic process in HT-29 cells Figure 7
Effects of simultaneous inhibition of Akt activity and progression of autophagic process in HT-29 cells. A, HT-29 
cells were exposed to DMSO (control), LY294002 (50 μmol/L) or Akt inhibitor IV (1.25 μmol/L) for 48 h and then subjected to 
immunofluorescent staining for LC3 as described in Materials and Methods. Bars, 20 μm. B, Quantification of acidic vesicular 
organelles by acridine orange staining using flow cytometry. HT-29 cells treated with DMSO (control), amino acid-deprived 
medium (AAS), LY294002 (50 μmol/L), or Akt inhibitor IV (1.25 μmol/L) for 48 h were stained with acridine orange and then 
the development of AVOs was analyzed as described in Materials and Methods. Left, FL1-H indicates the intensity of green fluo-
rescence that is endogenous to the nucleus. FL3-H indicates the intensity of red fluorescence. Top of the grid was considered as 
AVOs. Right, Columns, mean (n = 3); bars, SD. *, P < 0.05, significantly different compared with the control. C, The sub-G1 pop-
ulation was quantified by flow cytometry after exposure to LY294002 (50 μmol/L) or Akt inhibitor IV (1.25 μmol/L) with or 
without bafilomycin A1 (10 nmol/L) or 3-MA (10 mmol/L) for 48 h. Columns, mean (n = 3); bars, SD. *, P < 0.05, significantly dif-
ferent compared with the control.
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Methods
Reagents
Genistein was purchased from Fujicco (Kobe, Japan).
Indole-3-carbinol, 3-methyladenine (3-MA), bafilomycin
A1, ribonuclease A (RNase A), propidium iodide, anti-β-
actin antibody and anti-LC3B antibody were purchased
from Sigma (Saint Louis, MO). LY294002, anti-phospho-
Akt (Ser473), anti-Akt, anti-phospho-mTOR (Ser2448),
anti-mTOR, anti-poly (ADP-ribose) polymerase (PARP),
and anti-cleaved caspase-3 antibodies were purchased
from Cell Signaling Technology (Beverly, MA). Z-VAD-
fmk, anti-XIAP, anti-survivin, anti-caspase-9 and anti-cas-
pase-8 antibodies were purchased from R&D Systems
(Minneapolis, MN). Akt inhibitor IV was purchased from
Carbiochem (San Diego, CA). Anti-phospho-caspase-9
antibody was obtained from Santa Cruz Biotechnology
(Santa Cruz, CA).
Cell culture
Human colon cancer HT-29 cells were cultured in Dul-
becco's modified Eagle's medium (DMEM) as described
previously [11]. For amino acid starvation, HT-29 cells
were maintained in amino acid-deprived DMEM pur-
chased from Cell Science & Technology Institute, Inc.
(Sendai, Japan).
Cell viability assay
HT-29 cells were seeded at 1.2 × 104 per well in 24-well
culture plates and incubated for 24 h. The cells were then
exposed to the indicated agents for the indicated times,
and cell viability was analyzed using a Guava EasyCyte
plus flow cytometer according to the manufacturer's
instructions (Guava Technologies Inc.).
Drug interaction analysis
The effect of drug combination was evaluated by combi-
nation index (CI) method using the CalcuSyn software
(Biosoft, Ferguson, MO), which is based on the median
effect model of Chou and Talalay [74]. HT-29 cells were
exposed to I3C at concentrations ranging from 200 μmol/
L to 600 μmol/L and to genistein at 26.7 μmol/L to 80
μmol/L, either alone or in a fixed ratio of 7.5:1 (I3C:gen-
istein), for 48 h. Then the cell viability assay was per-
formed as described above and data obtained from the
assay were used to calculate values of fraction affected (Fa)
using the following formula: Fa = 1 - (cell viability of
treated group (%)/cell viability of control group (%)).
Such experimental data were entered into the CalcuSyn
interface and used to calculate combination index (CI)
values. Serial CI values over an entire range of drug-effect
levels (Fa) were then calculated. These data were used to
generate Fa-CI plots, from which synergy or antagonism
can be identified. Synergy, additivity, and antagonism are
defined as CI<1, CI = 1, and CI>1, respectively.
Detection of apoptosis
For the detection and analysis of apoptosis, the nuclei of
cells were stained with propidium iodide and measured
using Becton Dickinson FACSCalibur as described previ-
ously [11]. For the observation of nuclear morphology,
cells treated under various conditions as indicated were
fixed in methanol, incubated with 4',6-diamidino-2-phe-
nylindole (DAPI) solution, and then analyzed using a flu-
orescence microscope (IX-70; Olympus, Tokyo, Japan).
Western blotting
Cells were lysed in RIPA buffer containing PhosSTOP
(Roche Applied Science, Mannheim, Germany). Fifty
micrograms of protein was resolved by 7.5%, 10% or 15%
SDS-PAGE and transferred to PVDF membranes (Milli-
pore, Bedford, MA). After being blocked, the membranes
were incubated with primary antibody. After washing, the
membranes were incubated with HRP-conjugated second-
ary antibody, as described previously [11]. The signals
were detected with the ECL western blot analysis system
(GE Healthcare, Piscataway, NJ).
Transmission electron microscopy
The treated cells were collected by trypsinization and fixed
with 1.5% glutaraldehyde for 2 h at 4°C and postfixed
with 2% osmium tetroxide for 2 h. After dehydration with
50% to 100% alcohol, the cells were embedded in Quetol
812 resin (Nissin EM, Tokyo, Japan). After polymeriza-
tion, ultrathin sections (80 nm) were collected on a cop-
per grid and stained with uranyl acetate for 15 min,
followed by lead citrate for 5 min, then representative
areas were observed under an electron microscope (H-
300, Hitachi, Tokyo, Japan).
Immunofluorescent staining of LC3
After treatment under various conditions as indicated, the
cells were fixed with 4% paraformaldehyde for 10 min,
permeabilized with 100 μg/ml of digitonin, rinsed three
times with PBS, blocked by 1% BSA for 1 h, and incubated
with an anti-LC3 antibody (MBL, Nagoya, Japan) for 1 h
at room temperature. The cells were washed, incubated
with FITC-conjugated secondary antibody for 30 min at
room temperature, washed again and observed under a
fluorescence microscope (IX-70, Olympus).
Quantification of acidic vesicular organelles (AVO) with 
acridine orange staining
To quantify the development of AVOs, we performed vital
staining with acridine orange as described previously
[27,28,36]. Briefly, HT-29 cells were stained with acridine
orange (1 μg/mL) for 15 min, collected by trypsinization,
washed with PBS and analyzed with FACSCalibur.Molecular Cancer 2009, 8:100 http://www.molecular-cancer.com/content/8/1/100
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Statistical analysis
Data were expressed as means ± SD for triplicate experi-
ments. The statistical evaluation of the data was done
using Student's t  test for simple comparison between
groups and treatments. P < 0.05 was considered statisti-
cally significant.
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